新薬動向：筋骨格疾患治療薬

Abstract

This chapter of New Drug Futures evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years and beyond in the musculoskeletal sector. The report includes unique sales forecasts by major product.

The full 400-page report, evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years and beyond. The report covers 8 key therapy areas (alimentary/metabolic, anti-infectives, cancer, cardiovascular, CNS, musculoskeletal, respiratory, vaccines) and includes unique sales forecasts by major product. Click here for more information. This chapter is available separately.

The musculoskeletal market is the sixth largest therapeutic category by sales and generated over US$228 billion (+0.8% YoY) in 2005. Sales grew strongly in the US and Europe which accounted for 54% and 23% of sales however, sales have slowed significantly, largely due to the withdrawal of a number of COX-2 inhibitors during 2004 and early 2005.

Two of the largest segments of the musculoskeletal market are rheumatoid arthritis (anti-rheumatics) and osteoporosis (bone calcium regulators). The remaining sales are derived from the treatment of a mixture of aetiologies such as anti-inflammatory conditions and muscle relaxants.

Table of Contents

CURRENT MARKET SIZE

ANTI-RHEUMATIC DRUG SALES

ANTI-OSTEOPOROSIS DRUG SALES

ADDRESSABLE PATIENT POPULATION

• RHEUMATOID ARTHRITIS
• OSTEOPOROSIS

CURRENT TREATMENTS

• RHEUMATOID ARTHRITIS TREATMENTS
• OSTEOPOROSIS TREATMENTS
• RHEUMATOID ARTHRITIS SALES DRIVERS
• OSTEOPOROSIS SALES DRIVERS
• RHEUMATOID ARTHRITIS SALES BREAKERS
• OSTEOPOROSIS SALES BREAKERS

FUTURE TREATMENTS

MARKET DYNAMICS - WINNERS & LOSERS

KEY DRUGS LAUNCHES BY 2010

KEY EVALUATION CRITERIA

KEY MUSCULOSKELETAL DRUG LAUNCHES BY 2010

• Actemra (Roche/Chugai)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management/clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings and approval
  • Sales forecasts and assumptions
  • Competitor Ratio Analysis
• Bazedoxifene (Wyeth)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management/clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings and approval
  • Sales forecasts and assumptions
  • Competitor Ratio Analysis
• Cimzia (UCB/Celltech)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management/clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings and approval
  • Sales forecasts and assumptions
  • Competitor Ratio Analysis
• CNTO 148 (Johnson & Johnson/Schering-Plough)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management/clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings and approval
  • Sales forecasts and assumptions
  • Competitor Ratio Analysis
• Denosumab (Amgen)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management/clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings and approval
  • Sales forecasts and assumptions
  • Competitor Ratio Analysis
• Entereg (GlaxoSmithKline/Adolor)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management/clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings and approval
  • Sales forecasts and assumptions
  • Competitor Ratio Analysis
• Febuxostat (TAP Pharmaceutical Products)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management/clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Risks associated with developing a drug within a therapeutic class
  • Filings and approval
  • Sales forecasts and assumptions
  • Competitor Ratio Analysis
• Orencia (Bristol-Myers Squibb)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
  • Management/clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Sales forecasts and assumptions
  • Competitor Ratio Analysis
• Preos (NPS Pharmaceuticals)
  • Novelty/rationale for mechanism of action
  • Proof of concept/clinical data
    • POWER Study
    • PaTH Study
  • Management/clinical expertise
  • Competition within the marketplace/gaining share of voice
  • Filings and approval
  • Sales forecasts and assumptions
  • Competitor Ratio Analysis

COMPETITOR RATIO ANALYSIS SUMMARY

COMPETITOR RATIO ANALYSIS - COMPANIES